<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="45999"><DrugName>amonafide L- malate</DrugName><DrugNamesKey><Name id="43034134">Xanafide</Name><Name id="42761367">amonafide L- malate</Name></DrugNamesKey><DrugSynonyms><Name><Value>amonafide L- malate</Value><Types><Type>USAN</Type></Types></Name><Name><Value>XLS-001</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>amonafide L-malate (iv, cancer), Antisoma</Value></Name><Name><Value>AS-1413</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Xanafide</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>618863-54-0</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>69408-81-7</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="14239">Antisoma plc</CompanyOriginator><CompaniesSecondary><Company id="14239">Antisoma plc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="45999" type="Drug"><TargetEntity id="337999" type="siDrug">XLS-001</TargetEntity></SourceEntity><SourceEntity id="14239" type="Company"><TargetEntity id="4295896407" type="organizationId">Sarossa Capital Ltd</TargetEntity></SourceEntity><SourceEntity id="1731" type="ciIndication"><TargetEntity id="D015470" type="MeSH"/><TargetEntity id="519" type="ORPHANET"/><TargetEntity id="-1550871001" type="omicsDisease"/><TargetEntity id="686" type="siCondition"/></SourceEntity><SourceEntity id="276" type="ciIndication"><TargetEntity id="C61" type="ICD10"/><TargetEntity id="10060862" type="MEDDRA"/><TargetEntity id="D011471" type="MeSH"/><TargetEntity id="-405461207" type="omicsDisease"/><TargetEntity id="637" type="siCondition"/><TargetEntity id="5083" type="siCondition"/></SourceEntity><SourceEntity id="49" type="ciIndication"><TargetEntity id="C50" type="ICD10"/><TargetEntity id="10006279" type="MEDDRA"/><TargetEntity id="D001943" type="MeSH"/><TargetEntity id="-436099203" type="omicsDisease"/><TargetEntity id="588" type="siCondition"/></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity></SourceEntity><SourceEntity id="142" type="Action"><TargetEntity id="419" type="Mechanism">DNA Topoisomerase II Inhibitors</TargetEntity></SourceEntity><SourceEntity id="750" type="Action"><TargetEntity id="1405" type="Mechanism">DNA-Intercalating Drugs</TargetEntity></SourceEntity><SourceEntity id="PTGT-01878" type="ciTarget"><TargetEntity id="99171" type="siTarget">DNA Topoisomerase II (fungal)</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C3">Phase 3 Clinical</PhaseTerminated><RegulatoryDesignations><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsSecondary><Indication id="1731">Acute myelogenous leukemia</Indication><Indication id="276">Prostate tumor</Indication><Indication id="49">Breast tumor</Indication></IndicationsSecondary><ActionsPrimary><Action id="142">Topoisomerase II inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="750">DNA intercalator</Action><Action id="1545">Anticancer</Action></ActionsSecondary><Technologies><Technology id="648">Intravenous formulation</Technology><Technology id="740">Infusion</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2017-08-24T04:06:06.000Z</LastModificationDate><ChangeDateLast>2016-09-27T00:00:00.000Z</ChangeDateLast><AddedDate>2003-07-23T10:14:18.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="14239" linkType="Company"&gt;Antisoma&lt;/ulink&gt;, following its acquisition of Xanthus Pharmaceuticals, was developing amonafide L-malate (AS-1413; XLS-001, Xanafide; structure shown), an ATP-independent  topoisomerase II inhibitor, for the potential iv infusion  treatment of secondary acute myeloid leukemia (AML) [&lt;ulink linkID="830110" linkType="Reference"&gt;830110&lt;/ulink&gt;], [&lt;ulink linkID="498380" linkType="Reference"&gt;498380&lt;/ulink&gt;], [&lt;ulink linkID="915642" linkType="Reference"&gt;915642&lt;/ulink&gt;].  In June 2007, the FDA agreed an SPA for a phase III  trial in secondary  AML [&lt;ulink linkID="804079" linkType="Reference"&gt;804079&lt;/ulink&gt;]; the US trial began in October 2007 and was scheduled for completion in August 2010 [&lt;ulink linkID="837273" linkType="Reference"&gt;837273&lt;/ulink&gt;], [&lt;ulink linkID="837109" linkType="Reference"&gt;837109&lt;/ulink&gt;]; in October 2009, the primary endpoint of the trial was amended, as a result of which, the SPA  was no longer valid [&lt;ulink linkID="1048313" linkType="Reference"&gt;1048313&lt;/ulink&gt;]. In February 2010, regulatory filings were expected in 2011 [&lt;ulink linkID="1075898" linkType="Reference"&gt;1075898&lt;/ulink&gt;]. In November 2008, Antisoma planned on seeking to outlicense the drug outside the US [&lt;ulink linkID="964435" linkType="Reference"&gt;964435&lt;/ulink&gt;]; in May 2010, following interest from several companies, Antisoma were also looking for potential licensing partners within the US [&lt;ulink linkID="1100129" linkType="Reference"&gt;1100129&lt;/ulink&gt;]. In January 2011, primary endpoint was not met in the phase III  trial   and the company discontinued  development of the drug [&lt;ulink linkID="1164705" linkType="Reference"&gt;1164705&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;The drug was previously being developed for breast cancer and prostate cancer. By July 2003, an initial phase II trial of amonafide malate in patients with advanced hormone-refractory prostate cancer had been completed [&lt;ulink linkID="498380" linkType="reference"&gt;498380&lt;/ulink&gt;]. At that time, additional phase II trials in prostate and breast cancer were planned [&lt;ulink linkID="497899" linkType="reference"&gt;497899&lt;/ulink&gt;]. By April 2004, a phase II trial in breast cancer patients was underway [&lt;ulink linkID="532561" linkType="reference"&gt;532561&lt;/ulink&gt;]. By September 2007, however, no further development in these indications had been reported.&lt;/para&gt;&lt;para&gt;By July 2003, Xanthus intended to develop amonafide malate as an orally administered drug [&lt;ulink linkID="498380" linkType="reference"&gt;498380&lt;/ulink&gt;]. However, in 2005, clinical trials were still being carried out using iv infusions [&lt;ulink linkID="602955" linkType="Reference"&gt;602955&lt;/ulink&gt;], [&lt;ulink linkID="629685" linkType="Reference"&gt;629685&lt;/ulink&gt;].  &lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In June 2010, the FDA granted  amonafide malate Fast Track  status for secondary AML [&lt;ulink linkID="1105576" linkType="Reference"&gt;1105576&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2007, the FDA  granted amonafide malate Orphan Drug status for AML [&lt;ulink linkID="756149" linkType="Reference"&gt;756149&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In October 2007, the drug received European Orphan Drug status for AML [&lt;ulink linkID="844951" linkType="Reference"&gt;844951&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Acute myeloid leukemia&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In June 2007, the FDA agreed an SPA for a phase III trial in secondary AML. The 350-patient, multicenter, open-label, randomized study would compare amonafide malate (600 mg/m2, iv)  in combination with cytarabine (200 mg/m2, iv) to daunorubicin (45 mg/m2, iv) plus cytarabine (200 mg/m2, iv). The primary endpoint was the rate of complete remission. Duration of remission  was  the secondary endpoint [&lt;ulink linkID="804079" linkType="Reference"&gt;804079&lt;/ulink&gt;]. By October 2007, the 42-month,  US trial (&lt;ulink linkID="40373" linkType="Protocol"&gt;NCT00509912&lt;/ulink&gt; alias &lt;ulink linkID="40373" linkType="Protocol"&gt;NCT00715637&lt;/ulink&gt;; 0001A3-300-GL) began dosing and was scheduled for completion in August 2010 [&lt;ulink linkID="837273" linkType="Reference"&gt;837273&lt;/ulink&gt;], [&lt;ulink linkID="837109" linkType="Reference"&gt;837109&lt;/ulink&gt;]. In November 2008, Antisoma planned to expand the study to include 450 patients in North America, Europe and other territories [&lt;ulink linkID="964435" linkType="Reference"&gt;964435&lt;/ulink&gt;]. In January 2009, it was reported at the 27th Annual JPMorgan Healthcare Conference in San Francisco, CA, that  results were expected in late 2010/early 2011 [&lt;ulink linkID="976989" linkType="Reference"&gt;976989&lt;/ulink&gt;]. In February 2009, the company reported that the ACCEDE trial would enroll 450 patients [&lt;ulink linkID="984341" linkType="Reference"&gt;984341&lt;/ulink&gt;]. In October 2009,  the company amended the protocol of the study, following talks with the FDA and the trial investigators. The primary endpoint, previously confirmed  remission rate, was to be  changed to initial remission rate and confirmed remission rate was to then become a secondary endpoint. Other secondary endpoints included duration of remission and overall survival. At that time, one-third of the  patient enrollment target had been recruited. Key data were expected to be released in late 2010 or early 2011 [&lt;ulink linkID="1048313" linkType="Reference"&gt;1048313&lt;/ulink&gt;]. By February 2010, over half of patients had been enrolled [&lt;ulink linkID="1075898" linkType="Reference"&gt;1075898&lt;/ulink&gt;]. By May 2010, over 75% of the patient enrollment target had been recruited [&lt;ulink linkID="1100129" linkType="Reference"&gt;1100129&lt;/ulink&gt;]. In September 2010, enrollment had been completed with over 420 patients enrolled [&lt;ulink linkID="1129342" linkType="Reference"&gt;1129342&lt;/ulink&gt;]. In January 2011, the  pivotal ACCEDE trial did not meet its primary endpoint [&lt;ulink linkID="1164705" linkType="Reference"&gt;1164705&lt;/ulink&gt;]. In June 2011, data were presented at the 47th ASCO meeting in Chicago, IL. No significant difference in complete remission rate (+/-  hematopoietic recovery) was observed between the two treatment arms. The 30-day mortality was 20.4% in patients treated with amonafide malate and cytarabine, and 12.4% in patients treated with daunorubicin and cytarabine [&lt;ulink linkID="1196137" linkType="Reference"&gt;1196137&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In October 2005, Xanthus started a multicenter, North American, phase II trial of amonafide malate in combination with  cytarabine in 60 patient with secondary AML. Subjects   would  receive  amonafide malate once a day for 5 days with a standard infusion of cytarabine for 7 days. The primary endpoint would be the rate of complete remission and secondary endpoints included duration of remission and overall survival [&lt;ulink linkID="629685" linkType="Reference"&gt;629685&lt;/ulink&gt;]. In June 2006, an independent DSMB cleared Xanthus to continue the study after reviewing interim data collected from the first 26 patients in the trial [&lt;ulink linkID="671378" linkType="Reference"&gt;671378&lt;/ulink&gt;]. Enrollment for the trial was completed ahead of schedule in December 2006 [&lt;ulink linkID="748358" linkType="Reference"&gt;748358&lt;/ulink&gt;]. In June 2007, clinical data from the trial were presented at the 43rd ASCO meeting in Chicago, IL. Amonafide malate treatment in combination with cytarabine was found to be associated with a favorable complete remission rate. A total of 44% of patients achieved complete remission. The combination was  well tolerated [&lt;ulink linkID="801404" linkType="Reference"&gt;801404&lt;/ulink&gt;]. In December 2008, similar data were presented at the 50th ASH meeting in San Francisco, CA [&lt;ulink linkID="966255" linkType="Reference"&gt;966255&lt;/ulink&gt;]. In November 2009, final follow-up data from 88 patients were expected to be presented at the 51st ASH meeting, New Orleans, LA, in December 2009 [&lt;ulink linkID="1056070" linkType="Reference"&gt;1056070&lt;/ulink&gt;]. In December 2009, final data were presented at the 51st ASH meeting in New Orleans, LA. At 24 months for all patients, the overall survival was 15% and the median overall survival was 200 days. For      responders the overall survival was 30% and the median overall survival 400 days. The overall survival of all responders who received post-remission therapy was 33% at 24 months and the median overall survival was 480 days. Among responders aged &amp;lt; 60 and &amp;gt;/= 60 years, the overall survival was 32 and 30%, respectively at 24 months [&lt;ulink linkID="1057906" linkType="Reference"&gt;1057906&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In May 2005, clinical data were presented at the 41st ASCO meeting in Orlando, FL. In a dose-escalated phase I trial, 26 patients with relapsed AML, secondary AML or blast crisis CML were administered cytarabine (200 mg/m2 iv) for 7 days plus  amonafide malate (600, 700 or 800 mg/m2 iv, 2 h daily) for 5 days. The dose-limiting toxicity consisted of mucositis and erythematous rash in 3 of 5 patients in the 800 mg/m2 cohort. The maximum tolerated dose was 700 mg/m2 when in combination with cytarabine. In terms of efficacy, the response rate was 46%; 10 of 26 patients had a complete response (CR). Median CR duration was 5 months, and two patients remained disease-free for over 2 years. A phase II  trial of amonafide malate plus cytarabine  in secondary AML was planned [&lt;ulink linkID="602955" linkType="Reference"&gt;602955&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Further clinical data were presented in May 2005 at the 41st ASCO meeting in Orlando, FL. In studies investigating the compound as a single agent, four out of 17 patients had  CR [&lt;ulink linkID="602955" linkType="Reference"&gt;602955&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Prostate cancer&lt;/subtitle&gt;In May 2004, Xanthus initiated a US phase I/II trial of amonafide malate in prostate cancer. The study was to use a predictive test for drug metabolism to determine an individual's dosing needs for amonafide malate and was to evaluate the efficacy of the drug as determined by various measures of PSA response and tumor response [&lt;ulink linkID="540354" linkType="reference"&gt;540354&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Phase II data on amonafide malate for advanced hormone-refractory prostate cancer were published in July 2003. An overall response rate of 12% was observed in 43 evaluable patients given amonafide malate at a dose of 225 mg/m2, iv, daily for 5 days every 21 days [&lt;ulink linkID="498380" linkType="reference"&gt;498380&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In September 2007, preclinical data were  published. The cytotoxic effect of amonafide malate was found to be unaffected by the over-expression of P-glycoprotein (Pgp+) in AML cell lines and  the drug was neither a substrate nor an inhibitor of Pgp. This indicated the  drug was not susceptible to multi-drug resistance due to Pgp.  In comparison, Pgp caused the rapid efflux of other  topoisomerase II inhibitors (daunorubicin, doxorubicin, &lt;ulink linkID="51929" linkType="Drug"&gt;idarubicin&lt;/ulink&gt;, &lt;ulink linkID="3072" linkType="Drug"&gt;etoposide&lt;/ulink&gt;, and &lt;ulink linkID="11519" linkType="Drug"&gt;mitoxantrone&lt;/ulink&gt;) from leukemia cell lines, resulting in decreased therapeutic concentrations [&lt;ulink linkID="830110" linkType="Reference"&gt;830110&lt;/ulink&gt;], [&lt;ulink linkID="830288" linkType="Reference"&gt;830288&lt;/ulink&gt;]. In December 2007, similar data were presented at the 49th ASH meeting in Atlanta, GA. Amonafide malate was also a poor substrate for MRP-1 and BCRP [&lt;ulink linkID="859953" linkType="Reference"&gt;859953&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2005,  data were presented at the 96th AACR meeting in Anaheim, CA. Against two colorectal cell lines (HT29 and HCT116), the combinations of &lt;ulink linkID="11981" linkType="Drug"&gt;XLS-002&lt;/ulink&gt; with &lt;ulink linkID="2871" linkType="Drug"&gt;irinotecan&lt;/ulink&gt;, &lt;ulink linkID="3792" linkType="Drug"&gt;oxaliplatin&lt;/ulink&gt; and etoposide were not synergistic. The combinations of  XLS-002 with varying concentrations of amonafide malate or 5-FU were also not synergistic. However, the combinations of  amonafide malate or 5-FU with varying concentrations of XLS-002 were both highly synergistic. At non-therapeutic doses of XLS-002, the amonafide malate- and 5-FU-induced growth inhibition increased from the expected 50% to greater than 80% [&lt;ulink linkID="597643" linkType="Reference"&gt;597643&lt;/ulink&gt;]. Against two human prostate cancer cell lines (PC3 and DU145), the combination of amonafide malate, docetaxel and paclitaxel were evaluated [&lt;ulink linkID="597644" linkType="Reference"&gt;597644&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2004, preclinical data were presented at the 27th Annual San Antonio Breast Cancer  Symposium in San Antonio, TX. When tested in four different breast cancer cell lines, administration of amonafide malate caused total growth inhibition comparable to taxanes and better total growth inhibition comparable to &lt;ulink linkID="3199" linkType="Drug"&gt;gemcitabine&lt;/ulink&gt; or &lt;ulink linkID="6408" linkType="Drug"&gt;vinorelbine&lt;/ulink&gt; [&lt;ulink linkID="577087" linkType="Reference"&gt;577087&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In July 2003, preclinical data on amonafide malate were reported at the 94th AACR meeting in Washington, DC. In in vitro studies, the cytotoxicity of amonafide malate and amonafide HCl was evaluated in three human cell lines, H460 (non-small cell lung cancer), SF268 (glioma) and MCF-7 (breast cancer). The GI50 values obtained for amonafide malate and amonafide HCl were 4.11 and 4.31 microM (H460), 7.7 and 8.3 microM (SF268) and 5.16 and 6.69 microM (MCF-7), respectively. In in vivo studies, MCF-7, COLO205 (colon cancer) and PC-3 (prostate cancer) tumors were implanted ip or sc into athymic nude mice. Amonafide malate (29.4 mg/kg) or amonafide HCl (22.6 mg/kg) were administered ip once daily for 5 days. In MCF-7 cells, amonafide malate and amonafide HCl induced net cell killing of 29% and 27%, respectively in tumors implanted ip, and 10% and 8%, respectively, in tumors implanted sc. In COLO205 cells, significant growth inhibition of 78% (ip) and 68% (sc) was observed for amonafide malate, compared with 80% (ip) and 74% (sc) for amonafide HCl. In PC-3 cells, amonafide malate and amonafide HCl inhibited growth by 76% and 74%, respectively, of tumors implanted ip, and 55% and 60%, respectively of tumors implanted sc [&lt;ulink linkID="497899" linkType="reference"&gt;497899&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In April 2004, Xanthus was granted the composition of matter patent, US-06693198, covering amonafide malate until 2022 [&lt;ulink linkID="532531" linkType="reference"&gt;532531&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Amonafide malate is a new salt form of the anticancer compound, amonafide, originally developed at &lt;ulink linkID="25389" linkType="Company"&gt;Knoll Pharmaceuticals&lt;/ulink&gt;. Xanthus expected the new salt form to have advantages in terms of manufacturing yield, and solubility, and bioavailability in oral formulations [&lt;ulink linkID="540354" linkType="reference"&gt;540354&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="14239">Antisoma plc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate>2011-01-31T00:00:00.000Z</StatusDate><Source id="1164705" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14239">Antisoma plc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate>2011-01-31T00:00:00.000Z</StatusDate><Source id="1164705" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14239">Antisoma plc</Company><Country id="WO">World</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate>2011-01-31T00:00:00.000Z</StatusDate><Source id="1164705" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14239">Antisoma plc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate>2007-09-14T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14239">Antisoma plc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="276">Prostate tumor</Indication><StatusDate>2007-09-14T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="14239">Antisoma plc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate>2003-07-14T00:00:00.000Z</StatusDate><Source id="498380" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14239">Antisoma plc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate>2005-05-17T00:00:00.000Z</StatusDate><Source id="602955" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14239">Antisoma plc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="276">Prostate tumor</Indication><StatusDate>2003-07-14T00:00:00.000Z</StatusDate><Source id="498380" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14239">Antisoma plc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate>2004-04-14T00:00:00.000Z</StatusDate><Source id="532531" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14239">Antisoma plc</Company><Country id="XD">North America</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate>2005-10-19T00:00:00.000Z</StatusDate><Source id="629685" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14239">Antisoma plc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate>2007-10-08T00:00:00.000Z</StatusDate><Source id="837109" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14239">Antisoma plc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate>2008-06-11T00:00:00.000Z</StatusDate><Source id="915642" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14239">Antisoma plc</Company><Country id="WO">World</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate>2008-06-11T00:00:00.000Z</StatusDate><Source id="915642" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><OwnerCompany id="14239">Antisoma plc</OwnerCompany><Country id="US">US</Country><Indication id="1731">Acute myelogenous leukemia</Indication><AwardedIndication>Treatment of secondary acute myeloid leukaemia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2010-06-03T00:00:00.000Z</MileStoneDate><Source id="1105576" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="14239">Antisoma plc</OwnerCompany><Country id="EU">EU</Country><Indication id="1731">Acute myelogenous leukemia</Indication><AwardedIndication>Treatment of acute myeloid leukaemia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="9">Withdrawn</DesignationApplicationStatus><MileStoneDate>2011-03-01T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="14239">Antisoma plc</OwnerCompany><Country id="EU">EU</Country><Indication id="1731">Acute myelogenous leukemia</Indication><AwardedIndication>Treatment of acute myeloid leukaemia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="5">Transfer of Ownership</DesignationApplicationStatus><MileStoneDate>2009-01-31T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="14239">Antisoma plc</OwnerCompany><Country id="EU">EU</Country><Indication id="1731">Acute myelogenous leukemia</Indication><AwardedIndication>Treatment of acute myeloid leukaemia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2007-10-22T00:00:00.000Z</MileStoneDate><Source id="844951" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="14239">Antisoma plc</OwnerCompany><Country id="EU">EU</Country><Indication id="1731">Acute myelogenous leukemia</Indication><AwardedIndication>Treatment of acute myeloid leukaemia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate>2007-09-12T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="14239">Antisoma plc</OwnerCompany><Country id="US">US</Country><Indication id="1731">Acute myelogenous leukemia</Indication><AwardedIndication>Treatment of acute myeloid leukemia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2006-12-20T00:00:00.000Z</MileStoneDate><Source id="756149" type="PR"/></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-01878"><Name>Topoisomerase II</Name><SwissprotNumbers><Swissprot>O16140</Swissprot><Swissprot>O24308</Swissprot><Swissprot>O61078</Swissprot><Swissprot>O93794</Swissprot><Swissprot>P06786</Swissprot><Swissprot>P08096</Swissprot><Swissprot>P12531</Swissprot><Swissprot>P15348</Swissprot><Swissprot>P27570</Swissprot><Swissprot>P30182</Swissprot><Swissprot>P30190</Swissprot><Swissprot>P34203</Swissprot><Swissprot>P41001</Swissprot><Swissprot>P87078</Swissprot><Swissprot>Q00942</Swissprot><Swissprot>Q01879</Swissprot><Swissprot>Q23670</Swissprot><Swissprot>Q5UQE6</Swissprot><Swissprot>Q9Y8G8</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="14239">Antisoma plc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20516">US Government</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="13">Drug - Funding</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>CN(C)CCN1C(=O)c2cccc3c2c(cc(c3)N)C1=O</Smiles><Smiles>CN(C)CCN1C(=O)c2cccc3c2c(cc(c3)N)C1=O.C([C@@H](C(=O)O)O)C(=O)O</Smiles></StructureSmiles><Deals><Deal id="132724" title="Antisoma to receive funding from the US Government to develop its AS-1413 for AML "/></Deals><PatentFamilies><PatentFamily id="1294140" number="WO-2008086008" title="Method of treating multidrug resistant cancers"/><PatentFamily id="400542" number="WO-03089415" title="Amonafide salts"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Antisoma plc" id="14239"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>